Metformin treatment in patients with type 2 diabetes (T2D) may have an added benefit – reduction in colorectal cancer (CRC) or colorectal adenoma incidence, a recent meta-analysis suggested.
Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).
A once-daily maintenance dose of vonoprazan 10 mg or 20 mg may be a suitable substitute to lansoprazole in reducing the risk of erosive oesophagitis (EE) recurrence, according to a phase III noninferiority study presented at DDW 2020.
Regular use of aspirin may reduce the risk of gastrointestinal cancers, according to two studies presented at DDW 2020.
Patients with irritable bowel syndrome with diarrhoea (IBS-D) who have not responded to other medications may benefit from rifaximin, post hoc analyses of the TARGET 3* trial showed.